ArticlePediatric research2026
Genomic alterations in pediatric tumors: clinical relevance and translational insights.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is the leading cause of disease-related mortality in children. Next-generation sequencing (NGS) has emerged as a critical tool in precision oncology, enabling the identification of somatic genomic alterations that may inform diagnosis, prognosis, and therapy. This study evaluated the clinical utility of NGS in Israeli pediatric cancer patients.
methodsWe conducted a retrospective analysis of pediatric patients with cancer who underwent NGS at Sheba Medical Center between 2016 and 2021. Bioinformatics pipelines were applied to detect and annotate genomic variants. Medical records were reviewed to correlate molecular findings with treatment modifications and clinical outcomes.
resultsA total of 97 patients were analyzed, revealing a heterogeneous spectrum of somatic alterations. Recurrent variants were observed in genes involved in DNA repair, cell cycle regulation, and signaling pathways. Several variants initially classified as of uncertain significance were subsequently reclassified as pathogenic in light of updated genomic knowledge. Comparative analysis demonstrated unique molecular features within the Israeli pediatric cancer population relative to international cohorts.
conclusionsComprehensive genomic profiling provides clinically meaningful insights in pediatric oncology. NGS facilitates the identification of actionable variants, supports personalized therapeutic strategies, and underscores the importance of continued genomic research and collaborative efforts in improving outcomes for children with cancer. IMPACT: NGS identifies actionable mutations in pediatric cancers, with known mutation patterns characterized in large international cohorts. This study adds novel insights into the mutation landscape of pediatric cancer patients. Nearly 25% benefited from NGS-informed therapy, supporting routine genomic profiling at diagnosis.
Identifiers
42595821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.